Open AIDS Clinical Trials in the Los Angeles Area

Note: The AT LAST study has officially been canceled. Details about this process will be published in the next issue of Women Alive newsletter.

UCLA -- 310.206.6414

OI Therapies (UCLA)

Ganciclovir implant + oral ganciclovir vs. cidofovir for CMV retinitis.

Fluconazole for oral candida; chronic vs. episodic treatment.

For Women (UCLA)

Phase III study of Accutane (oral isotrention) vs. observation for low-grade cervical dysplasia. 310.206.6414.

For Pregnant Women (UCLA)

Study 321: Phase I, safety, tolerance and pharmacokinetics of Abacavir (Ziagen) with standard AZT therapy in newborns of HIV infected women.

Study 326: Phase I & II -- all babies will get AZT. Most babies will get a vaccine that might help them fight off HIV.

Study 331: to decide the best dose of AZT for premature infants exposed to HIV.

USC -- 213.343.8324

Llame al 213.740.0299

A wide variety of clinical studies are open to women, including trials with antivirals and protease inhibitors. Also those looking to prevent and treat opportunistic infections.

La Escuela de asistencia social en la U.S.C. está llevando a cabo una encuesta de encuesta es completamente confidencial, y se paga $20.

Acute Infection

If you think you might have a recent exposure to HIV, give us a call -- 213.351.8195 ext.8175.

HIV+ Women Needed

Women ages 18-50 are needed for a study to measure the effects of testosterone replacement on body weight, and muscle mass. Incentive payments provided. Call: 310.222.8152.

Drug Resistance Testing

A study of a test that may determine sensitivity to antiretroviral treatment. It's open to women and men. Call Corie at 310.358.2429. Para informacion en espanol, llame 310.360.3876.

Pain or Numbness

A 5-week study to see if gabapentin works for neuropathy. Everyone will receive medication. 310.358.2429.

World Wide Trial

Evaluation of ABT-378/ritonavir, a new protease inhibitor. This study is in the early phases. 1.800.313.2130.

Donate Your Brain

A project to study the effects of HIV on the brain. You must donate your brain after your death. 800.791.4966.

PMPA

Phase II, double blind, placebo controlled. PMPA is a new antiretroviral drug being studied. Participants have an 85% chance of receiving drug. 310.358.2429.

HIV+ Volunteers Needed For Research Study involves only one brief office visit. ARA is conducting a study of the OraQuick HIV test. THIS STUDY DOES NOT INVOLVE A DRUG. The study involves only one clinic visit that consists of a single blood draw, a single oral specimen and finger stick, and a 15-minute, confidential interview. Volunteers will receive $30 compensation for their inconvenience. Requirements HIV+, 18 - 65 years old. T-cell count that has never dropped below 200. No history of opportunistic infections. Call 310.358.2429